Elevated placental growth factor (PIGF) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy

被引:13
|
作者
Tarnow, L
Astrup, AS
Parving, HH
机构
[1] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
[2] Aarhus Univ, Fac Hlth Sci, Aarhus, Denmark
关键词
placental growth factor; diabetic nephropathy; cardiovascular disease;
D O I
10.1080/00365510500235970
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background and Aim. Placental growth factor (PIGF) is up-regulated in early and advanced atherosclerotic lesions, acts as a primary inflammatory instigator of atherosclerotic plaque instability, and may be an independent biomarker of adverse outcome in patients with acute coronary syndromes. In diabetic nephropathy the relative cardiovascular mortality and morbidity is increased and therefore, this study investigated the prognostic value of PIGF in a large cohort of type 1 diabetic patients with and without diabetic nephropathy. Research Design and Methods. In a prospective, observational follow-up study 190 type 1 diabetic patients with overt diabetic nephropathy (116 men, age (mean (SD)) 41 +/- 10 years, duration of diabetes 28 +/- 8 years, glomerular filtration rate (GFR) 76 +/- 33 mL/min/1.73 m(2)) and a matched control group of 174 patients with normoalbuminuria (104 men, age 43 +/- 10 years, duration of diabetes 27 +/- 9) were followed for 10 years (range: 0-10.3). The primary endpoint was a composite endpoint of cardiovascular death, hospitalization for myocardial infarction or stroke, coronary artery bypass grafting or percutanous coronary intervention, ischaemic amputation or peripheral bypass-surgery. Plasma PIGF was determined by an enzyme linked immunosorbent assay at baseline. Results. During 10 years of follow-up 74 patients (39 %) with diabetic nephropathy reached the primary endpoint versus only 18 (10 %) of normoalbuminuric patients, log rank test; p<0.001. During follow-up 16 (25 %) patients in the lowest, 24 (39 %) in the middle and 34 (52 %) patients in the upper tertile reached the primary cardiovascular endpoint, p=0.007. Hazard ratios in the second and third tertile as compared with the first tertile were 1.76 (0.92-3.38) and 2.64 (1.41-4.91) (p=0.009). Cox regression analyses including PIGF concentration as a continuous variable revealed an unadjusted hazard ratio of the primary endpoint for each 1 ng /L increase in PIGF of 1.10 (1.03-1.16), p=0.002; covariate adjusted hazard ratio 1.07 (1.00-1.14), p=0.03. Conclusions Increased PIGF is a new independent predictor of cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
引用
收藏
页码:73 / 79
页数:7
相关论文
共 50 条
  • [1] Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy
    Astrup, AS
    Tarnow, U
    Rossing, P
    Hansen, BV
    Hilsted, J
    Parving, HH
    [J]. DIABETES CARE, 2006, 29 (02) : 334 - 339
  • [2] SERUM PLACENTAL GROWTH FACTOR (PLGF) PREDICTS ALL-CAUSE AND CARDIOVASCULAR MORTALITY BUT NOT DETERIORATION OF KIDNEY FUNCTION IN TYPE 1 DIABETIC PATIENTS WITH DIABETIC NEPHROPATHY
    Theilade, S.
    Lajer, M.
    Jorsal, A.
    Tarnow, L.
    Parving, H. H.
    Rossing, P.
    [J]. JOURNAL OF HYPERTENSION, 2010, 28 : E125 - E126
  • [3] Plasma concentration of asymmetrical dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy
    Lajer, M.
    Tarnow, L.
    Jorsal, A.
    Teerlink, T.
    Parving, H.-H.
    Rossing, P.
    [J]. DIABETOLOGIA, 2007, 50 : S468 - S468
  • [4] Plasma concentration of asymmetric climethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy
    Lajer, Maria
    Tarnow, Lise
    Jorsal, Anders
    Teerlink, Tom
    Parving, Hans-Henrik
    Rossing, Peter
    [J]. DIABETES CARE, 2008, 31 (04) : 747 - 752
  • [5] Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy
    Tarnow, L
    Fagerudd, JA
    Rossing, P
    Poirier, O
    Nielsen, FS
    Parving, HH
    [J]. DIABETES CARE, 2000, 23 (01) : 30 - 33
  • [6] Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy
    Hovind, P
    Tarnow, L
    Oestergaard, PB
    Parving, HH
    [J]. KIDNEY INTERNATIONAL, 2000, 57 : S56 - S61
  • [7] Elevated vascular endothelial growth factor in type I diabetic patients with diabetic nephropathy
    Hovind, P
    Tarnow, L
    Ostergaard, PB
    Parving, HH
    [J]. DIABETOLOGIA, 1998, 41 : A318 - A318
  • [8] Elevated Circulating Pigment Epithelium-derived Factor Predicts the Progression of Diabetic Nephropathy in Type 2 Diabetic Patients
    Hui, Elaine
    Yeung, Chun-Yip
    Lee, Paul C. H.
    Woo, Yu-Cho
    Fong, Carol H. Y.
    Xu, Aimin
    Lam, Karen Siu Ling
    [J]. DIABETES, 2014, 63 : A137 - A138
  • [9] Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes
    Tarnow, L
    Hovind, P
    Teerlink, T
    Stehouwer, CDA
    Parving, HH
    [J]. DIABETES CARE, 2004, 27 (03) : 765 - 769
  • [10] Cardiovascular morbidity and early mortality clusters in parents of IDDM patients with diabetic nephropathy
    Tarnow, L
    Fagerud, J
    Rossing, P
    Nielsen, FS
    Cambien, F
    Parving, HH
    [J]. DIABETOLOGIA, 1998, 41 : A291 - A291